ArticleInternational journal of molecular sciences2023

Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma.

Ioannis Ntanasis-Stathopoulos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.